Minimal Residue Disease Testing Market Size and Trends - 2031
微量残留疾病检测市场规模预计将从 2023 年的 35.5 亿美元激增至 2031 年的 89.4 亿美元;预计 2023 年至 2031 年市场复合年增长率为 12.24%。
分析师观点:
该报告包含了增长前景当前最低残留疾病检测市场趋势及其在预测期内的可预见影响。白血病、淋巴瘤和实体瘤等各种癌症的全球患病率不断上升,以及对微残留疾病检测产品和服务的需求。医疗保健提供者和研究人员认识到最小残留疾病评估在监测治疗反应、预测复发和指导治疗干预方面的临床效用。随着微量残留疾病检测不断发展并成为癌症管理的关键工具,市场参与者专注于创新、标准化和可及性,以利用微量残留疾病检测市场中的利润丰厚的机会。< /p>
市场概况:
将微小残留病检测纳入健康保险计划以及该检测方法在实体病中的应用肿瘤诊断是推动微小残留病检测市场的因素。随着全球消费者意识的提高,对微小残留病检测的需求也随之增加。医疗保健提供者和研究人员认识到这一趋势,并努力通过将微小残留病检测融入临床实践来满足患者的期望。推动最小残留疾病检测市场增长的其他关键因素包括癌症患病率的上升和新一代测序技术的日益使用。
Minimal Residue Disease Testing Market: Strategic Insights
Minimal Residue Disease Testing Market
-
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cagr.png)
CAGR (2023 - 2031)
12.24%
-
Market Size 2023
US$ 3.55 Billion
-
Market Size 2031
US$ 8.94 Billion
Key Players
- Adaptive Biotechnologies,
- Natera,
- Bio-Rad Laboratories,
- F-Hoffmann La Roche Ltd,
- Guardant Health,
- LabCorp,
- Sysmex Corporation,
- ARUP Laboratories,
- Invivoscribe, Inc.,
- NeoGenomics Laboratories, Inc.,
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 亚太地区(中国、日本、韩国、印度、澳大利亚、亚太地区其他地区)
- 欧洲(德国、法国、英国、意大利、俄罗斯、欧洲其他地区)
- 中东和非洲(沙特阿拉伯、阿联酋、南非、中东和非洲其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
Market Segmentation
技术(流式细胞术、PCR、NGS、其他)
癌症类型(白血病、淋巴瘤、实体瘤、多发性骨髓瘤)
最终用户(医院、专科诊所、诊断实验室等)
Minimal Residue Disease Testing Market: Strategic Insights
-
CAGR (2023 - 2031)12.24% -
Market Size 2023
US$ 3.55 Billion -
Market Size 2031
US$ 8.94 Billion
![](https://www.theinsightpartners.com/assets/images/rd_int_img/tip-logo.jpg)
Key Players
- Adaptive Biotechnologies,
- Natera,
- Bio-Rad Laboratories,
- F-Hoffmann La Roche Ltd,
- Guardant Health,
- LabCorp,
- Sysmex Corporation,
- ARUP Laboratories,
- Invivoscribe, Inc.,
- NeoGenomics Laboratories, Inc.,
Regional Overview
![](https://www.theinsightpartners.com/assets/images/rd_int_img/ig-regional.png)
- 北美(美国、加拿大、墨西哥)
- 亚太地区(中国、日本、韩国、印度、澳大利亚、亚太地区其他地区)
- 欧洲(德国、法国、英国、意大利、俄罗斯、欧洲其他地区)
- 中东和非洲(沙特阿拉伯、阿联酋、南非、中东和非洲其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
Market Segmentation
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_danger.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_primary.png)
市场驱动因素:
癌症患病率不断上升推动市场增长
2020年,癌症病例数达到1930万,癌症相关死亡人数达到996万。根据国际癌症研究机构的数据,到 2025 年,癌症病例数预计将达到 2190 万,到 2030 年将达到 2460 万。根据美国临床肿瘤学会 2021 年 2 月的报告,约 235,760 名成年人(119,100 名男性和 119,100 名男性)美国有 116,6600 名女性被诊断患有肺癌。 GLOBOCAN 2020数据显示,印度占全球新增癌症病例总数的18.3%;此外,宫颈癌占所有癌症病例的9.4%。根据美国癌症协会 (ACS) 的数据,2021 年美国新发现近 26,560 例胃癌病例,其中男性 16,160 例,女性 10,400 例。美国国家乳腺癌基金会2021年7月发布的统计数据显示,约63%的乳腺癌患者被诊断为局部期乳腺癌,27%被诊断为区域期乳腺癌,6%被诊断为远处(转移)疾病。此外,全球血癌患病率的不断上升,增强了对更好的治疗选择和去除残留癌细胞的准确性的需求。根据美国癌症协会公布的统计数据,2022 年 1 月,美国估计新诊断出 34,920 例多发性骨髓瘤病例。癌症病例数量的激增可能会迫使各国政府推出新的癌症预防计划,而预计将推动微量残留疾病检测市场的增长。
细分分析:
微量残留疾病检测市场分析是通过考虑以下部分进行的:技术、癌症类型和最终用途。
基于技术,微量残留疾病检测市场细分为流式细胞术、PCR、NGS等。流式细胞术领域在 2023 年占据最大的市场份额。PCR 领域预计在 2023 年至 2031 年期间复合年增长率最高,达到 12.39%。 PCR方法可以根据突变或染色体变化等特征性遗传异常来检测癌细胞。该技术必然涉及微小 DNA 或 RNA 片段的扩增,以帮助它们的可检测性和可计数性。即使使用含有少量癌细胞的样本(例如血细胞或骨髓),也可以识别遗传异常。 PCR 的高灵敏度使其能够检测到 100,000 个正常细胞中低至 1 个的癌细胞。获得检测结果可能需要5-14天。
市场上根据癌症类型分为白血病、淋巴瘤、实体瘤和多发性骨髓瘤。 2023 年,实体瘤领域占据了最大的微量残留疾病检测市场份额。该领域的市场增长归因于正在进行的专注于评估实体瘤患者的研究。对于采用 MRD 检测来检测非血液恶性肿瘤,目前还没有公认的建议。循环肿瘤 DNA (ctDNA) 作为实体瘤治疗后残留分子疾病诊断的预后生物标志物的方法正在迅速纳入临床试验设计和转化研究。该方法适用于标准临床护理。尽管ctDNA检测技术发展迅速,但这些检测方法的低灵敏度降低了其在各种临床应用中检测MRD的有用性。
根据最终用户,微残留疾病检测市场分为医院、专科诊所、诊断实验室等。 2022 年,医院细分市场占据最大的微量残留疾病检测市场份额,预计 2023-2031 年复合年增长率最高,达到 12.79%。医院占有很大的市场份额,这主要归因于它们在急症护理和患者管理中的作用。对于患有严重健康状况的患者来说,入院往往是必要的,因为医院设施可以提供更好的决策能力,使医生和医疗保健专业人员能够分析患者并为他们提供更好的治疗选择。
区域分析:
微量残留病检测市场报告的范围包括北美、欧洲、亚太地区、中东和美国。非洲、南美和非洲中美洲。 2023年北美市场估值为9.3亿美元,预计到2031年将达到23.4亿美元;预计2023-2031年复合年增长率为12.12%。癌症发病率显着增加;引进最新技术;已建立的蛋白质组学、基因组学和肿瘤学研究基础设施巩固了北美作为微量残留病检测市场主要贡献者的地位。
亚太地区微量残留病检测市场测试市场预计将创下12.68%的最快复合年增长率。该地区,尤其是印度和中国等国家,拥有规模庞大的制药业。 2021年10月,泛生子(中国)和江苏复星(中国)开始在中国商业化MRD检测测试。他们过去还在中国的血液科医院和诊所推广了Seq-MRD。该测试具有准确性、高通量、成本效益、一致性和快速周转时间。研究被主要市场参与者视为开发新颖测试的主要关注领域。除了对研究的日益关注之外,对癌症患者治疗后监测的需求不断增长,继续推动亚太地区微量残留疾病检测市场的进步。此外,医疗保健基础设施的改善和新兴制药行业使亚太地区成为市场显着增长和发展的关键枢纽。
主要参与者分析:强>
适应性生物技术;纳特拉; Bio-Rad 实验室; F-霍夫曼拉罗氏有限公司;守护健康;实验室公司;希森美康公司;奥雅纳实验室; Invivoscribe 公司;新基因组学实验室有限公司;和 Mission Bio, Inc 是微量残留疾病检测市场报告中介绍的主要参与者。
最新进展:
在微量残留疾病检测市场运营的公司采用并购作为关键增长战略。根据公司新闻稿,以下列出了一些最近的市场发展:
- 2023 年 4 月,Quest Diagnostics 收购了 Haystack Oncology,通过采用先进的液体活检技术来扩大其肿瘤产品组合。这一补充使 Quest 能够通过提供具有高灵敏度诊断功能的工具和其他产品来改善个性化癌症治疗。
- 2023 年 4 月,Integrated DNA Technologies 推出了 Archer FUSIONPlex Core Solid Tumor Panel。这一突破性的测试解决方案经过改进和完善,涵盖了更广泛的单核苷酸变异 (SNV) 和插入缺失(即核苷酸的插入、缺失或插入和缺失)功能或有助于癌症研究。
- 2022 年 12 月, Adaptive Biotechnologies 推出了 clonoSEQ,用于使用循环肿瘤 DNA (ctDNA) 评估弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者的微小残留病。
- 2022 年 10 月,Adaptive Biotechnologies 与 Epic Systems Corporation 合作整合 clonoSEQ分析进入 Epic 的综合电子病历 (EMR) 系统。 clonoSEQ 检测受到美国食品和药物管理局 (FDA) 的监测和批准,用于检测与多发性骨髓瘤 (MM)、慢性淋巴细胞白血病 (CLL) 和 B 细胞急性淋巴细胞白血病 (ALL) 相关的微小残留病。
- 2022 年 8 月,罗氏推出了首款数字 LightCycler 系统,该系统旨在准确量化痕量的特定 RNA 和 DNA。
- 2022 年 2 月,Personalis 与 Moores 癌症中心合作,支持对晚期实体瘤患者进行临床诊断测试。肿瘤和血液系统恶性肿瘤。此次合作的重点是使用新推出的液体活检检测方法来检测高度敏感的微小残留病和癌症复发。
Minimal Residue Disease Testing Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 3.55 Billion |
Market Size by | US$ 8.94 Billion |
Global CAGR | 12.24% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By 技术(流式细胞术、PCR、NGS、其他) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The global minimal residual disease testing market, based on technique is divided into flow cytometry, PCR, NGS, and others. The flow cytometry segment held the largest market share in 2023, and the PCR segment is likely to register the highest CAGR of 12.39% during 2023–2031. Based on cancer type, the market is segmented into leukemia, lymphoma, solid tumors, and multiple myeloma. The solid tumors segment held the largest market share in 2023, and the same segment is estimated to grow at the fastest CAGR during 2023–2031. The lymphoma segment held the second largest market share in 2023. Based on end user, the market is segmented into hospitals, specialty clinics, diagnostic laboratories, and others. The hospitals segment held the largest minimal residue disease testing market share in 2022, and the same is anticipated to register the highest CAGR of 12.79% during 2023–2031.
The minimal residual disease testing market is expected to be valued at US$ 8.94 billion in 2031.
The minimal residual disease testing market was valued at US$ 3.55 billion in 2023.
The minimal residual disease testing market majorly consists of the players such as Adaptive Biotechnologies; Natera; Bio-Rad Laboratories; F-Hoffmann La Roche Ltd; Guardant Health; LabCorp; Sysmex Corporation; ARUP Laboratories; Invivoscribe, Inc.; NeoGenomics Laboratories, Inc.; and Mission Bio, Inc.
The factors driving the growth of the minimal residual disease testing market include the surging prevalence of cancer and the increasing use of next-generation sequencing technology.
Patients achieving complete hematologic remission after blood cancer treatment may foster residual cancer cells in the bone marrow or peripheral blood. These cells can result in relapse, as they persist at levels so low that they cannot be detected by conventional cytomorphology. Similar is the case with several other cancer conditions, including solid tumors and multiple myeloma. Minimal residual disease testing is employed to detect and quantify cancer cells existing in small numbers in a patient's body. This testing is performed by using sensitive technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to identify measurable residual disease at the molecular level. Minimal residual disease testing is clinically important because it helps monitor response to treatment, predicts risk of relapse, guides personalized therapies, and serves as an endpoint in clinical trials.
The List of Companies - Minimal Residual Disease Testing Market
- Adaptive Biotechnologies
- Natera
- Bio-Rad Laboratories
- F-Hoffmann La Roche Ltd
- Guardant Health
- LabCorp
- Sysmex Corporation
- ARUP Laboratories
- Invivoscribe, Inc.
- NeoGenomics Laboratories, Inc.
- Mission Bio, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.